François Mach

Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease

Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes

Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the <scp>CAPTURE</scp> study

New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?

European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology

Novel Blood Biomarkers for a Diagnostic Workup of Acute Aortic Dissection

Cognition After Lowering LDL-Cholesterol With Evolocumab

Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Cognitive Function in a Randomized Trial of Evolocumab

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Design and rationale of the <scp>EBBINGHAUS</scp> trial: A phase 3, double‐blind, placebo‐controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid‐lowering therapy—A cognitive study of patients enrolled in the <scp>FOURIER</scp> trial

Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol

Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors

Anti‐ApoA‐1 IgG serum levels predict worse poststroke outcomes

Decreased serum <scp>PCSK</scp>9 levels after ischaemic stroke predict worse outcomes

Serum levels of anti-apolipoprotein A-1 IGG are associated with long-term disability and cerebral lesion volume in acute ischemic stroke patients

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke

Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways

Discovery and refinement of loci associated with lipid levels